Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Kuria Therapeutics Logo
Kuria Therapeutics Growth Score
80
CB Rank
401807
Heat Score
18
Kuria Therapeutics operates as a pharmaceutical company.
Founded
obfuscation
PrivateSeed Little Rock, Arkansas, United States1-10 www.kuriatx.com
Biotechnology
Pharmaceutical
Overview

Kuria Therapeutics
Growth Score
80
Heat Score
18

Growth Score80
-9 pts
in past quarter
Heat Score 18
-23 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Kuria Therapeutics

CB Rank
401807
Kuria Therapeutics operates as a pharmaceutical company.
Founded
obfuscation
PrivateSeed Little Rock, Arkansas, United States1-10 www.kuriatx.com
Biotechnology
Pharmaceutical

Funding Rounds

Seed
OBF
in
obfuscation

Details

Legal Name Kuria Therapeutics, Inc.
Operating Status Active
Company Type For Profit
About the Company
Kuria Therapeutics operates as a pharmaceutical company that develops novel ophthalmic and dermal therapeutics.
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

KTX-1161
A topical ophthalmic formulation of SCO-116 designed to activate the Nrf2 pathway for treating corneal endothelial diseases.
SCO-116
A novel, selective small-molecule activator of the Nrf2 pathway for potential treatment of ocular and dermal diseases involving oxidative stress and inflammation.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed

Funding Rounds

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed
obfuscation
Seed Round - Kuria Therapeutics Logo
Seed Round - Kuria Therapeutics
—
obfuscation
— Seed

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Contacts 6
News

News and Press

News•Apr 29, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 5, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Sep 8, 2022
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

IT Spend

$48.6KThis year, Kuria Therapeutics is projected to spend $48.6K on IT, according to Aberdeen.

Active Website Tech Count

2Kuria Therapeutics is actively using 2 technologies for its website, according to BuiltWith. These include Common Crawl and  CommonCrawl Top 50m.
Sub-Organizations
Frequently Asked Questions

Where is Kuria Therapeutics's headquarters? Kuria Therapeutics is located in Little Rock, Arkansas, United States.When was the last funding round for Kuria Therapeutics? Kuria Therapeutics closed its last funding round on
obfuscation
from a Seed round.Who are Kuria Therapeutics's competitors? Alternatives and possible competitors to Kuria Therapeutics may include Atsena Therapeutics, Aurion Biotechnologies, and  Bausch & Lomb.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(3ff49e4 1)
|